Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (monocytes) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 1 Parkinson's papers of 692 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12611
Sealed predictions
- CXCL3 in dopamine neurons, braak-0.23 (p 0.549) → -0.06 (p 0.874)receipt 12616
Swarm cases
receipt 12616: CXCL3 in dopamine neurons, braak
- power
- full sample -0.23 (p 0.351, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.18 (p 0.487, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.21 (p 0.413, n 18). could be the mix.
- skeptic
- leave-one-out range -0.39 to -0.14, sign flips 0; without severely affected donors -0.23 (p 0.351, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CXCL3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts